Inside an MDMA-Assisted Therapy Session: Preparation, the Dosing Day, Integration

People deciding whether to seek MDMA-assisted therapy almost always ask the same question: what would actually happen to me? The answer is reasonably well documented, because the Phase 3 trials wrote the schedule down. Here is that schedule in plain language.

Stage one: screening and preparation

Before anyone receives a dose, there is a medical and psychological screen. Trial protocols exclude people with uncontrolled high blood pressure, significant cardiovascular disease, a history of epilepsy, liver disease, and a range of other conditions, and they screen for current substance dependence and active suicidality. The New Zealand and Australian guideline group's clinical practice guidance recommends strongly against using the treatment in patient groups that were excluded from the trials for safety reasons — including people who are pregnant or breastfeeding and people with uncontrolled hypertension.

Preparation sessions then do three jobs: establish the therapeutic relationship, agree what the dosing session will address, and set out what to do if things go badly. The risk-benefit literature in JAMA Psychiatry argues this last part is not optional — contingency plans for severe reactions should be agreed before the dose, not improvised afterwards.

Stage two: the dosing day

The session itself is long. In the MAPS Phase 3 protocol it runs six to eight hours from dosing to discharge, with the patient in a comfortable room rather than a clinical one. The typical physical setup is two reclining chairs or a bed, eyeshades, a speaker for music, and a therapist on either side.

What is being monitored: blood pressure, heart rate, and temperature at regular intervals. MDMA raises both heart rate and blood pressure — the American Journal of Psychiatry review notes that in trial conditions blood pressures generally stayed below the hypertensive threshold of 140/90, but that this is a monitoring requirement, not a guarantee.

What the patient does: mostly turns inward. The therapists do not lead the session with questions. They hold the space, respond when the patient reaches for them, and intervene if distress becomes unmanageable. Many patients describe the first hour or two as physically strange — jaw tension, nausea, temperature changes — before the emotional material arrives.

What the therapists do: stay present the entire time. In the two-therapist model one typically handles physiological monitoring while the other stays with the patient emotionally, and they rotate.

Stage three: the same day, and the next day

Patients are not discharged as soon as the effects fade. Discharge criteria in trial protocols include stable vital signs and the ability to orient and walk safely, which usually means the patient stays into the evening and is required to have a companion drive them home. The following day is normally kept clear.

Stage four: integration

The integration session, usually within days, is where the treatment either becomes useful or does not. This is where the experience is narrated, where meaning is drawn out, and where the patient and therapists work out which specific changes to make. Trial protocols schedule several non-dosing therapy sessions across the follow-up period for exactly this reason.

People who report the clearest benefit tend to describe integration as the harder and less glamorous half of the treatment: the dosing day produced a shift, and the following weeks decided whether the shift held.

How many dosing sessions

The Phase 3 programme used up to three dosing sessions, spaced a few weeks apart, with the option of a third if the first two had not produced sufficient change. That means the full course runs over roughly three months, not one day.

What to ask a clinic before you commit

• How many dosing sessions are included, and what happens if two are not enough?
• Who monitors blood pressure, and what is the plan if it goes too high?
• How many preparation and integration sessions are included in the price?
• What screening is done, and what conditions rule you out?
• What happens if you become suicidal in the weeks afterwards?

If a provider cannot answer those five questions in writing, that is the answer.